Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process
MD, JD, MSHP Emily B Rubin, Jonathan A Boiarsky, Lauren A Canha, Anita Giobbie-Hurder, Mofei Liu, Matthew J Townsend, Michael Dougan
Open Forum Infectious Diseases, doi:10.1093/ofid/ofab546
Background. Given the challenges associated with timely delivery of monoclonal antibody (mAb) therapy to outpatients with coronavirus disease 2019 (COVID-19) who are most likely to benefit, it is critical to understand the effectiveness of such therapy outside the context of clinical trials. Methods. This was a case-control study of 1257 adult outpatients with COVID-19, ≥65 years of age or with body mass index (BMI) ≥35, who were entered into a lottery for mAb therapy. Results. Patients who were called to be offered mAb therapy had a statistically significant 44% reduction in the odds of hospitalization within 30 days of a positive severe acute respiratory syndrome coronavirus 2 test compared with those who were not called (odds ratio [OR], 0.56; 95% CI, 0.36-0.89; P = .01). Patients who actually received bamlanivimab had a statistically significant 68% reduction in the odds of hospitalization compared with those who did not receive bamlanivimab (OR, 0.32; 95% CI, 0.11-0.93; P = .04). Conclusions. This study supports the effectiveness of bamlanivimab in reducing COVID-19-related hospitalizations in patients ≥65 or with BMI ≥35.
Author contributions. Dr. Rubin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
References
Chen, Nirula, Heller, BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Chen, Winkler, Case, In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains, Nature
Corwin, Ender, Sahu, The efficacy of bamlanivimab in reducing emergency department visits and hospitalizations in a real-world setting, Open Forum Infect Dis
Dougan, Nirula, Azizad, BLAZE-1 Investigators. Bamlanivimab plus etesevimab in mild or moderate Covid-19, N Engl J Med
Ganesh, Philpot, Bierle, Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019, J Infect Dis
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Jenks, Aslam, Horton, Early monoclonal antibody administration can reduce both hospitalizations and mortality in high-risk outpatients with COVID-19, Clin Infect Dis
Kumar, Wu, Sosor, Real-world experience of bamlanivimab for COVID-19: a case-control study, Clin Infect Dis
O'brien, Forleo-Neto, Musser, Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV antibody combination to prevent Covid-19, N Engl J Med
Planas, Veyer, Baidaliuk, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature
Rubin, Dryden-Peterson, Hammond, A novel approach to equitable distribution of scarce therapeutics: institutional experience implementing a reserve system for allocation of COVID-19 monoclonal antibodies, Chest,
doi:10.1016/j.chest.2021.08.003Verderese, Stepanova, Lam, Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate COVID-19. A real-world experience, Clin Infect Dis,
doi:10.1093/cid/ciab579Webb, Buckel, Vento, Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19, Open Forum Infect Dis
Weinreich, Sivapalasingam, Norton, Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
{ 'indexed': {'date-parts': [[2023, 5, 8]], 'date-time': '2023-05-08T07:53:04Z', 'timestamp': 1683532384149},
'reference-count': 20,
'publisher': 'Oxford University Press (OUP)',
'issue': '12',
'license': [ { 'start': { 'date-parts': [[2021, 11, 3]],
'date-time': '2021-11-03T00:00:00Z',
'timestamp': 1635897600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2021, 12, 1]]},
'abstract': '<jats:title>Abstract</jats:title>\n'
' <jats:sec>\n'
' <jats:title>Background</jats:title>\n'
' <jats:p>Given the challenges associated with timely delivery of monoclonal '
'antibody (mAb) therapy to outpatients with coronavirus disease 2019 (COVID-19) who are most '
'likely to benefit, it is critical to understand the effectiveness of such therapy outside the '
'context of clinical trials.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Methods</jats:title>\n'
' <jats:p>This was a case–control study of 1257 adult outpatients with '
'COVID-19, ≥65 years of age or with body mass index (BMI) ≥35, who were entered into a lottery '
'for mAb therapy.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Results</jats:title>\n'
' <jats:p>Patients who were called to be offered mAb therapy had a '
'statistically significant 44% reduction in the odds of hospitalization within 30 days of a '
'positive severe acute respiratory syndrome coronavirus 2 test compared with those who were '
'not called (odds ratio [OR], 0.56; 95% CI, 0.36–0.89; P=.01). Patients who actually received '
'bamlanivimab had a statistically significant 68% reduction in the odds of hospitalization '
'compared with those who did not receive bamlanivimab (OR, 0.32; 95% CI, 0.11–0.93; '
'P=.04).</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Conclusions</jats:title>\n'
' <jats:p>This study supports the effectiveness of bamlanivimab in reducing '
'COVID-19-related hospitalizations in patients ≥65 or with BMI ≥35.</jats:p>\n'
' </jats:sec>',
'DOI': '10.1093/ofid/ofab546',
'type': 'journal-article',
'created': {'date-parts': [[2021, 11, 4]], 'date-time': '2021-11-04T02:49:49Z', 'timestamp': 1635994189000},
'source': 'Crossref',
'is-referenced-by-count': 4,
'title': 'Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in '
'a Lottery-Based Allocation Process',
'prefix': '10.1093',
'volume': '8',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1788-3618',
'authenticated-orcid': False,
'given': 'Emily B',
'family': 'Rubin',
'sequence': 'first',
'affiliation': [ { 'name': 'Division of Pulmonary and Critical Care Medicine, Department of '
'Medicine, Massachusetts General Hospital, Boston, Massachusetts, '
'USA'}]},
{ 'given': 'Jonathan A',
'family': 'Boiarsky',
'sequence': 'additional',
'affiliation': [ { 'name': 'University of California, Los Angeles Medical Center, Los '
'Angeles, California, USA'}]},
{ 'given': 'Lauren A',
'family': 'Canha',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Gastroenterology, Department of Medicine, '
'Massachusetts General Hospital, Boston, Massachusetts, USA'}]},
{ 'given': 'Anita',
'family': 'Giobbie-Hurder',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Biostatistics, Department of Data Science, '
'Dana-Farber Cancer Institute, Boston, Massachusetts, USA'}]},
{ 'given': 'Mofei',
'family': 'Liu',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Biostatistics, Department of Data Science, '
'Dana-Farber Cancer Institute, Boston, Massachusetts, USA'}]},
{ 'given': 'Matthew J',
'family': 'Townsend',
'sequence': 'additional',
'affiliation': [{'name': 'Duke University Medical Center, Durham, North Carolina, USA'}]},
{ 'given': 'Michael',
'family': 'Dougan',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Gastroenterology, Department of Medicine, '
'Massachusetts General Hospital, Boston, Massachusetts, USA'}]}],
'member': '286',
'published-online': {'date-parts': [[2021, 11, 3]]},
'reference': [ {'key': '2021120719080297900_CIT0001', 'author': 'US Food and Drug Administration.'},
{'key': '2021120719080297900_CIT0002', 'author': 'Regeneron.'},
{ 'key': '2021120719080297900_CIT0003',
'doi-asserted-by': 'crossref',
'first-page': '229',
'DOI': '10.1056/NEJMoa2029849',
'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with '
'Covid-19.',
'volume': '384',
'author': 'Chen',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '2021120719080297900_CIT0004',
'doi-asserted-by': 'crossref',
'first-page': '238',
'DOI': '10.1056/NEJMoa2035002',
'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with '
'Covid-19.',
'volume': '384',
'author': 'Weinreich',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '2021120719080297900_CIT0005',
'volume-title': 'Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for '
'treatment of COVID-19',
'author': 'US Food and Drug Administration (FDA).'},
{ 'key': '2021120719080297900_CIT0006',
'doi-asserted-by': 'crossref',
'first-page': '1382',
'DOI': '10.1056/NEJMoa2102685',
'article-title': 'Bamlanivimab plus etesevimab in mild or moderate Covid-19.',
'volume': '385',
'author': 'Dougan',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '2021120719080297900_CIT0007',
'doi-asserted-by': 'crossref',
'first-page': '1184',
'DOI': '10.1056/NEJMoa2109682',
'article-title': 'Subcutaneous REGEN-COV antibody combination to prevent Covid-19.',
'volume': '385',
'author': 'O’Brien',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '2021120719080297900_CIT0008',
'volume-title': 'Guidance for allocation of COVID-19 monoclonal antibody therapeutics',
'author': 'Massachusetts Department of Public Health.'},
{ 'key': '2021120719080297900_CIT0009',
'first-page': 'S0012-3692(21)03622-9',
'article-title': 'A novel approach to equitable distribution of scarce therapeutics: '
'institutional experience implementing a reserve system for allocation '
'of COVID-19 monoclonal antibodies.',
'author': 'Rubin',
'year': '2021',
'journal-title': 'Chest'},
{ 'key': '2021120719080297900_CIT0010',
'author': 'United States Centers for Disease Control and Prevention.',
'year': '2021'},
{ 'key': '2021120719080297900_CIT0011',
'article-title': 'Real-world experience of bamlanivimab for COVID-19: a case-control '
'study.',
'author': 'Kumar',
'year': '',
'journal-title': 'Clin Infect Dis'},
{ 'key': '2021120719080297900_CIT0012',
'article-title': 'Early monoclonal antibody administration can reduce both '
'hospitalizations and mortality in high-risk outpatients with COVID-19.',
'author': 'Jenks',
'year': '',
'journal-title': 'Clin Infect Dis'},
{ 'key': '2021120719080297900_CIT0013',
'doi-asserted-by': 'crossref',
'first-page': 'XXX',
'DOI': '10.1093/ofid/ofab331',
'article-title': 'Real-world effectiveness and tolerability of monoclonal antibody '
'therapy for ambulatory patients with early COVID-19.',
'volume': '8',
'author': 'Webb',
'year': '2021',
'journal-title': 'Open Forum Infect Dis'},
{ 'key': '2021120719080297900_CIT0014',
'doi-asserted-by': 'crossref',
'first-page': '1278',
'DOI': '10.1093/infdis/jiab377',
'article-title': 'Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab '
'among high-risk patients with mild to moderate coronavirus disease '
'2019.',
'volume': '224',
'author': 'Ganesh',
'year': '2021',
'journal-title': 'J Infect Dis'},
{ 'key': '2021120719080297900_CIT0015',
'doi-asserted-by': 'crossref',
'DOI': '10.1093/ofid/ofab305',
'article-title': 'The efficacy of bamlanivimab in reducing emergency department visits '
'and hospitalizations in a real-world setting.',
'volume': '8',
'author': 'Corwin',
'year': '2021',
'journal-title': 'Open Forum Infect Dis'},
{ 'key': '2021120719080297900_CIT0016',
'doi-asserted-by': 'crossref',
'first-page': 'ciab579',
'DOI': '10.1093/cid/ciab579',
'article-title': 'Neutralizing monoclonal antibody treatment reduces hospitalization for '
'mild and moderate COVID-19. A real-world experience.',
'author': 'Verderese',
'year': '2021',
'journal-title': 'Clin Infect Dis'},
{ 'key': '2021120719080297900_CIT0017',
'doi-asserted-by': 'crossref',
'first-page': '632',
'DOI': '10.1001/jama.2021.0202',
'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab '
'on viral load in patients with mild to moderate COVID-19: a randomized '
'clinical trial.',
'volume': '325',
'author': 'Gottlieb',
'year': '2021',
'journal-title': 'JAMA'},
{'key': '2021120719080297900_CIT0018', 'author': 'US Food and Drug Administration.'},
{ 'key': '2021120719080297900_CIT0019',
'doi-asserted-by': 'crossref',
'first-page': '276',
'DOI': '10.1038/s41586-021-03777-9',
'article-title': 'Reduced sensitivity of SARS-CoV-2 variant Delta to antibody '
'neutralization.',
'volume': '596',
'author': 'Planas',
'year': '2021',
'journal-title': 'Nature'},
{ 'key': '2021120719080297900_CIT0020',
'doi-asserted-by': 'crossref',
'first-page': '103',
'DOI': '10.1038/s41586-021-03720-y',
'article-title': 'In vivo monoclonal antibody efficacy against SARS-CoV-2 variant '
'strains.',
'volume': '596',
'author': 'Chen',
'year': '2021',
'journal-title': 'Nature'}],
'container-title': 'Open Forum Infectious Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab546/41073072/ofab546.pdf',
'content-type': 'application/pdf',
'content-version': 'am',
'intended-application': 'syndication'},
{ 'URL': 'https://academic.oup.com/ofid/article-pdf/8/12/ofab546/41640764/ofab546.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'syndication'},
{ 'URL': 'https://academic.oup.com/ofid/article-pdf/8/12/ofab546/41640764/ofab546.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 12, 7]],
'date-time': '2021-12-07T19:08:23Z',
'timestamp': 1638904103000},
'score': 1,
'resource': {'primary': {'URL': 'https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofab546/6420437'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 11, 3]]},
'references-count': 20,
'journal-issue': {'issue': '12', 'published-print': {'date-parts': [[2021, 12, 1]]}},
'URL': 'http://dx.doi.org/10.1093/ofid/ofab546',
'relation': {},
'ISSN': ['2328-8957'],
'subject': ['Infectious Diseases', 'Oncology'],
'published-other': {'date-parts': [[2021, 12, 1]]},
'published': {'date-parts': [[2021, 11, 3]]}}
